Introduction the transcription factor nFκB represents a family of five mammalian proteins (c-rel, rela, relB, nFκB1 and nFκB2) that regu late a wide variety of genes involved in immune and inflammatory responses, among many other functions. 1 some of the genes regulated by nFκB include cytokines, such as interleukin (il)-1, il-2, il-6, il-12 and tumor necrosis factor (tnF), chemo kines, interferons, and antiapoptotic proteins, such as BirC2 (also known as ciaP1), BirC3 (also known as ciaP2) and BCl2l1 (also known as Bcl-Xl). 1 in humans, dysregulation of nFκB activity is associated with, among other diseases, arthritis, auto immunity, alzheimer disease, diabetes and osteoporosis. 2, 3 thus, components of the signal transduction pathway of nFκB are potential treatment targets in these diseases.
inactive nFκB dimers reside in the cytoplasm through interaction with one of a family of inhibitory proteins called inhibitors of κB (iκBs). activation of nFκB occurs through a wide variety of stimuli that lead to the activation of iκB kinase (iKK). iKK is a complex of three subunits: iKKα (also known as iKK1), iKKβ (also known as iKK2), and iKKγ (also known as nemo). Phos phorylation of iκB by iKK targets the iκB for polyubiquitination and degradation. 1 the nFκB homodimers or heterodimers can then enter the nucleus and activate transcription.
NFκB in osteoclasts
osteoclasts are specialized cells of the monocyte-macrophage lineage that are responsible for bone resorption, whereas osteoblasts are responsible for building new bone. During adulthood there is a balance of osteoblasts and osteoclasts that facilitates normal bone remodeling and turnover. an increase in the osteoclast-to-osteoblast ratio has been implicated in osteoporosis, metastatic bone disease and rheumatoid arthritis.
the nFκB pathway in osteoclasts has been extensively reviewed elsewhere. [4] [5] [6] receptor activator of nuclear factor κB ligand (ranKl; also known as tnF ligand superfamily, member 11) is an essential cytokine in osteoclastogenesis, along with macrophage colony stimulating factor (m-CsF). 7 ranKl is expressed in osteoblasts, marrow stromal cells and t cells, and binds to the ranK receptor (also known as tnF receptor superfamily, member 11a) on osteoclast progenitor cells. 7 Binding of ranKl to the ranK receptor leads to activation of tnF receptor-associated factors (traFs) 1, 2, 3, 5 and 6, and subsequent nFκB-mediated upregulation of osteoclast target genes. 5 nFκB signaling, activated by ranKl, tnF or il-1, can lead to the induction of osteoclast differentiation genes, prolonged survival of osteoclasts and increased bone resorption. two main targets of nFκB in osteoclasts are the transcription factors c-Fos and nFatc1, 8 which are transcriptionally upregulated by nFκB in response to ranKl signaling. in parallel, il-1 activates nFκB to upregulate the expression of osteoclast genes CD40LG (also known as TRAP), CTSK (cathepsin K) and OSCAR (osteoclast associ ated receptor). 9 treatments targeting the ranKl or nFκB pathway, or both, have the potential to prevent bone degradation. a peptide inhibitor of nFκB activation, which prevents iKKα and iKKβ from binding to iKKγ, has been shown to block osteoclastogenesis and collagen-induced arthritis in mice. 10 the ranKl pathway can be in hibited by osteoprotegerin (oPG; also known as tnF receptor superfamily, member 11b), which acts as a decoy receptor for ranKl. Denosumab, a humanized monoclonal antibody against ranKl that acts like oPG to neutralize ranKl activity, is currently in latestage clinical development as a treatment for osteoporosis. 3 
Genetic models of NFκB in bone
Rela knockout mice are embryonic lethal, preventing study of the effects of rela on the adult skeleton. Relb knockout mice are viable, with no change in the uninduced osteoclast number and no apparent osteoblast phenotype. 11 However, relB is required for osteoclast differentiation in vitro and for optimal osteoclast induction in response to inflammation in vivo. abstract | NFκB is a family of transcription factors involved in immunity and the normal functioning of many tissues. It has been well studied in osteoclasts, and new data indicate an important role for NFκB in the negative regulation of bone formation. In this article, we discuss how NFκB activation affects osteoblast function and bone formation. In particular, we describe how reduced NFκB activity in osteoblasts results in an increase in bone formation via enhanced c-Jun N-terminal kinase (JNK) activity, which regulates FOSL1 (also known as Fra1) expression. Furthermore, we discuss how estrogen and NFκB crosstalk in osteoblasts acts to oppositely regulate bone formation. Future NFκB-targeting treatments for osteoporosis, rheumatoid arthritis and other inflammatory bone diseases could lead to increased bone formation concurrent with decreased bone resorption. stromal cells) that contribute to the osteopetrotic phenotype of these mice. How ever, bone formation in vivo was not evaluated in these mice. nonetheless, to address the question of the micro environment, co-cultures of osteoblasts and osteoclasts from wild-type and Nfkb1/Nfkb2 doubleknockout mice were established in vitro. isolated wild-type calvarial osteoblasts are not capable of inducing osteo clastogenesis from splenic precursors derived from Nf kb1/Nf kb2 double-knockout mice, whereas wild-type osteoblasts can induce osteoclast formation from wild-type splenic cells. 13 this finding suggests that nFκB1 and nFκB2 are necessary in osteoclasts for osteoclast formation. in addition, osteoblasts from the Nfkb1/Nfkb2 doubleknockout mice are also capable of inducing osteoclasts from wild-type splenic cells, 13 indicating no role for nFκB1 and nFκB2 in osteoblastic induction of ranKl or in other mechanisms of osteoblastic regulation of osteoclasts. However, a role for nFκB1 and nFκB2 in osteoblast differentiation and mineralization was not examined.
iKKβ, a catalytic subunit of the iKK complex that mediates nFκB activation, has important roles in both osteoblast and osteoclast formation, 14 whereas iKKα has no apparent role (or a redundant role). iKKα-deficient mice die shortly after birth and have rudimentary limbs, shorter jaws and absent or truncated tails, among other abnormalities. 15 the limb defects are not due to problems in bone or cartilage. interestingly, replacement of iKKα only in basal epidermal keratinocytes (the transgene is under the transcriptional control of cytokeratin 14 [CK14], creating the CK14-Ikka mouse) can correct the skeletal defects, 16 suggesting no role for iKKα in osteoblasts. Ikka AA mice, which are homo zygous for a knock-in mutant allele in which the activation loop serines of iKKα-whose phosphoryla tion is required for its activation-are replaced with alanines, are viable with lymphoid defects. Histomorphometric analysis of the bones of Ikka AA mice shows no change in the number of osteoclasts or osteoblasts in comparison to wild-type mice, 14 confirming the results observed in CK14-Ikka mice. in comparison, iKKβ knockout mice are embryonic lethal. to study a bone phenotype, conditional iKKβ knockout mice (IkkbΔ) were created using mice with an mx1 promoter (induced by interferon or polyinosinicpolycytidylic acid) driving Cre-recombinase expression crossed with mice harboring a 'floxed' Ikkb allele. in contrast to Ikka AA mice, IkkbΔ knockout mice were osteopetrotic and had decreased numbers of osteoblasts and osteoclasts at 7 months of age compared with wild-type mice.
14 to further define how nFκB regulates osteoblast function and bone formation, Chang et al. 20 generated transgenic mice in which a dominant negative (Dn) iKKγ allele is expressed under the control of the osteoblast-specific bone γ-carboxyglutamate protein 2 (Bglap2; also known as osteocalcin) promoter. as a result, nFκB activity is inhibited in mature osteoblasts, but not in osteoclasts. the Bglap2-iKK-Dn mice have increased bone mineral density (BmD) at the ages of 2 and 4 weeks. the 2-weekold transgenic mice had the same number of osteoblasts and osteoclasts as wild-type mice, but an increased rate of bone formation. Furthermore, inhibition of nFκB in osteoblasts in vitro led to an increase in osteoblast mineralization, demon strating the cell-autonomous activity of nFκB. interestingly, there was no change in the number of osteoclasts, suggesting that nFκB in osteoblasts does not control osteoblastic regulation of osteoclastogenesis. 1 there is no apparent skeletal phenotype in adult Bglap2-iKK-Dn mice: the BmD and bone Bv/tv (bone volume/ trabecular volume) are increased in the transgenic mice at 2 and 4 weeks of age, but not at 2 or 6 months. 20 nFκB activity is high during the development of wild-type bone (J. Chang et al., unpublished data), but not in adult bone, which accounts for the phenotype observed in the young and ovariectomized Bglap2-iKK-Dn mice (see below).
while there is no change in the number of osteoblasts in Bglap2-iKK-Dn mice, mice with global iKKβ knockout do have decreased osteoblast numbers.
14 osteoclastic iKKβ may have an effect on the number of osteoblasts; however, osteoblast-specific knockout of iKKβ would be needed to verify the differences in the models.
Decreased nFκB activity was found to increase c-Jun n-terminal kinase (JnK) activity in osteoblasts from Bglap2-iKK-Dn mice (Figure 1) . nFκB has been shown to upregulate BirC2 and GaDD45B to suppress proapoptotic JnK signaling in fibroblasts 17, 18 and osteoclasts; 19 however, it is not yet known how nFκB regulates JnK in osteoblasts. is there a direct interaction between nFκB and JnK, or does nFκB increase transcription of a gene that regulates JnK activity as it does in fibroblasts?
activated JnK has been shown to regulate the transcription of activator protein 1 (aP-1) in other tissues. as such, expression levels of several members of the aP-1 family were tested in Bglap2-iKK-Dn osteoblasts, and the expression of Fos-related antigen 1 (Fra1; encoded by Fosl1) was shown to be increased (Figure 1) . 20 the importance of Fra1 in osteoblast function was demonstrated in vitro using short hairpin rna (shrna) directed against Fosl1. Knockdown of Fosl1 in osteoblasts resulted in decreased bone matrix mineralization. Knockout of Fosl1 in mice also demonstrates that Fra1 is necessary for bone matrix formation. 21 in summary, a reduction in nFκB activity in osteoblasts results in an increase in bone formation via an increase in JnK activity, which regulates Fra1 expression. Julien et al. 22 demonstrated that Fra1 directly binds to the promoter of matrix Gla protein (mGP), a key regulator of bone formation. these data suggest that nFκB represses osteoblast mineralization through a series of transcriptional and signaling events in mature osteoblasts. perspeCtives in addition to a role for nFκB in young, developing mice, studies in ovariectomized mice suggest that nFκB is involved in postmenopausal osteoporosis. 20 after ovari ectomy, Bglap2-iKK-Dn mice had less bone loss in the vertebrae and femurs than did wild-type mice owing to a higher bone formation rate, again demonstrating a role for nFκB in the inhibition of osteoblast function and bone formation. Furthermore, Fra1 expression was significantly higher in the osteoblasts of ovariectomized transgenic mice than in wild-type mice or sham-operated mice.
Inhibition of bone formation
elevated expression of tnF, il-1, il-6 and il-7 has been detected in a variety of chronic inflammatory bone diseases, including rheumatoid arthritis, osteoarthritis, osteoporosis and periodontal diseases. interestingly, these cytokines are produced by macrophages, lymphocytes, osteoblasts and bone marrow stromal cells 23, 24 under the regulation of nFκB, and also stimulate nFκB signaling in the target cells. as a result, the number of osteoclasts is increased, leading to bone resorption, and osteoblast activity is repressed, leading to decreased mineralization.
that tnF can inhibit osteoblast differen tiation and bone formation is well known. using two models of osteoblast differentiation-fetal rat calvarial preosteoblasts and a murine calvarial clonal osteoblastic cell line (mC3t3-e1)-Gilbert et al. 25 found that tnF inhibited cell differentiation by downregulating the transcription of Runx2, which regulates the expression of bone matrix proteins. runX2 protein stability has also been shown to be destabilized by tnF. 26 Furthermore, tnF also represses the osteoblast transcription factor osterix (osX). 27 as a result of the reduced levels of the key osteoblast transcription factors runX2 and osX, tnF inhibits the expression of the skele tal matrix proteins type i collagen and osteocalcin. 28, 29 During menopause, as estrogen levels decrease, BmD also decreases. several papers have suggested different molecular mechanisms to explain this effect of estrogen in bone. 30 a decrease in estrogen levels at menopause has been associated with an increase in serum levels of il-1, il-6, il-7 and tnF. 23 in addition to repressing cytokine production, estrogen also increases transcription of Fas ligand (also known as CD178) in osteoblasts, which leads to apoptos is of osteoclasts. 31 several hypotheses have been proposed for how 17β-estradiol (e2) can repress pro inflammatory cytokines (Figure 2 ). 32 estrogen receptor α (er-α) has been shown to associate with nFκB, which prevents nFκB binding to Dna and inhibits transcription of cytokines. a second hypothesis is that er-α regulates iκB or iKK activity. a third hypothesis is that estrogen-induced er-α can sequester co activators (such as tiF2; also known as GriP1 or nCoa2), p300 or CreBBP (also known as CreBbinding protein [CBP]) away from nFκB. a fourth hypothesis is that er-α prevents iκB degradation, preventing nFκB activation. However, the studies that gave rise to these hypotheses were not performed in primary osteoblast cells. whether there is a tissuespecific mechanism of estrogen-mediated repression of nFκB in osteoblasts is unclear.
tnF is regulated in opposite directions by e2 and nFκB. Both nFκB and unliganded er-α are recruited directly to the TNF promoter to activate transcription after treatment with tnF (tnF can upregulate its own transcription in an auto-regulatory loop). repression of tnF mrna occurs as early as 30 min after e2 treatment, indicating that tnF is a direct target of e2. e2 leads to recruitment of tiF2, a member of the p160 family of coactivators and corepressors that is a corepressor for tnF, 33 and subsequent down-regulation of tnF. e2 did not alter recruitment of nFκB to the TNF promoter.
mice null for tnF and the tnF type 1 receptor were analyzed for their bone phenotype and showed increased BmD, resulting from elevated bone mineralization. no change in osteoclast number or serum carboxy-terminal collagen crosslinks (CtX, a marker of bone resorption) was observed. Furthermore, blockade of the nFκB pathway using inhibitory peptides enhanced osteoblast differentiation and mineralization. 34 in comparison, transgenic mice overexpressing tnF are a well-established model for arthritis and osteoporosis.
35 not only do they have an increased number of osteoclast pre cursor cells, 36 but the osteoblasts from these mice have a diminished capacity for mineralization. 26 together, these mouse models support a role for tnF activation of nFκB in the suppression of osteoblast function.
the post-ovariectomy decrease in BmD observed in mice or rats can be prevented by blocking cytokines that are normally repressed by e2. independent neutralization of tnF, il-1, il-6 or il-7 has been shown to inhibit bone resorption. [37] [38] [39] interestingly, a more favorable outcome is seen when both perspeCtives tnF and il-1 are blocked compared with blockade of either cytokine alone. 40 this was demonstrated in ovariecto mized mice treated with either il-1 receptor antagonist or tnF-binding protein. no effect was seen on bone when tnF and il-1 were blocked in sham-ovariectomized mice, demonstrating the speci ficity of this effect to estrogen-regulated pathways. 40 to elucidate the pathway downstream of cytokines in osteoblasts, Chang et al. 20 used antibodies specific for the active form of the nFκB subunit rela to show an increase in nFκB activity in osteoblasts after ovariectomy. By contrast, there was little active rela observed in bones from Bglap2-iKK-Dn mice. this is further evidence that estrogen regulates nFκB in osteoblasts in vivo; however, the mechanism of rela activation remains unknown. more importantly, bone loss was found to be markedly reduced in Bglap2-iKK-Dn mice after ovariec tomy, suggesting that the activation of nFκB impairs osteoblastic bone formation. Based on our studies described here and other works on osteoclasts, we propose a novel model of osteoporosis: the activation of nFκB due to estrogen deficiency not only promotes osteoclast activation, osteoclast survival and bone resorption, but simultaneously inhibits osteoblast function.
Future research directions
although better studied in t cells and osteoclasts, it is becoming evident that the nFκB pathway is also important in osteoblasts. studies have shown a role for rela in the regulation of the JnK pathway and Fra1. However, rela is only one piece of the nFκB pathway. what are the receptors and ligands that activate the nFκB pathway in osteoblasts? Cytokines, tnF, bacterial lipopolysaccharide and viruses are just a few of the agonists that activate nFκB in other tissues. 1 Could there be osteoblast-specific agonists or receptors, or both? in osteoclasts, traFs 1, 2, 3, 5 and 6 regulate nFκB downstream of ranK signaling: which traFs, if any, activate iKK in osteoblasts?
in addition to osteoporosis, levels of proinflammatory cytokines are increased and bone formation is inhibited in rheuma toid arthritis, osteoarthritis and the gum disease periodontitis. in the future, it will be important to test, by use of iKK-Dn mice, whether the activation of nFκB in osteoblasts in these diseases is responsible for the compromised bone formation.
the genes that are directly regulated by nFκB in osteoblasts remain to be identified.
while Fra1 is an indirect target of nFκB through the JnK signaling pathway, it is possible that nFκB may induce other genes that directly inhibit osteoblast function. tnF has been found to inhibit the expression of the osteoblast master transcription factors runX2 and osX: 25, 27 it remains to be determined whether and how nFκB has a role in the inhibition of runX2 and osX via tnF.
another potential question concerns the function of nFκB at each stage of osteoblast differentiation. the inhibition of nFκB promotes alkaline phosphatase activity, Col1A1 transcription and osteocalcin acti vity in C2C12 mesenchymal cells. as osteoblasts are derived from mesenchymal stem cells (msCs), it is important to rigidly test whether nFκB has a role in the regulation of osteoblast differentiation from msCs. msCs have been proposed for use in tissue regeneration and repair, and if the inhibition of nFκB promotes differentiation, the inhibition of nFκB could help to promote regenera tion and to inhibit local inflammation.
Implications for therapy
Currently, many drugs used in the treatment of osteoporosis are bone resorption inhibitors. 41 although these types of drugs inhibit bone resorption, they are unable to increase or restore bone mass in human patients with osteoporosis. as patients with osteoporosis may have lost more than 50% of bone mass at the time of diagnosis, the lack of anabolic activity of antiresorptive agents is a critical shortcoming in this therapeutic approach. 42 according to our studies, targeting nFκB might provide a novel and efficacious treatment strategy in patients with osteoporosis or other inflammatory bone diseases. the proteasome inhibitor bortezomib, which is used to treat multiple myeloma, has been found to promote bone formation by stabilizing runX2, 43 and it is known that proteasome inhibitors inhibit nFκB by blocking iκBα degradation. 1, 44 according to our results, bortezomib might also promote bone formation through the inhibition of nFκB. However, it should be pointed out that nFκB has also been found to have a critical role in the inhibition of apoptosis. 45, 46 as apoptosis of osteoblasts has been suggested to have a role in the development of osteoporosis, 47 there could be concerns that the inhibition of nFκB in differentiated osteoblasts might induce massive apoptosis, resulting in more deleterious bone loss. However, we found that the inhibition of nFκB in iKK-Dn mice did not increase osteoblast apoptosis in vivo. 20 it is well known that various growth factors are highly deposited in the bone marrow and bone matrix. these growth factors may promote cell survival through akt or erK signaling pathways and overcome nFκB inhibition. in fact, bone morpho genetic protein signaling has previously been shown to overcome tnF-mediated apoptosis indepen dently of nFκB. 48 Conclusions nFκB has important roles in both osteoblasts and osteoclasts that affect bone regulation. Chang et al. 20 have shown that a reduction in nFκB activity in osteoblasts results in an increase in bone formation. Furthermore, we propose that the reduction of nFκB activity mediated by estrogen not only reduces osteoclast activation and bone resorption, but simultaneously increases osteoblast function. identifying a drug that not only inhibits bone resorption, but also promotes new bone formation, would be a major therapeutic advance. targeting nFκB could provide a novel and efficacious treatment strategy for osteoporosis and other inflammatory bone diseases.
